Wednesday, July 7, 2021, London -- David Sinclair, Ph.D., will present the latest research on the topic Novel approaches to delay and reverse aging at the worlds' largest annual Aging Research and Drug Discovery conference (8th ARDD). David A. Sinclair, Ph.D. A.O. is a tenured Professor in the Genetics Department at the Blavatnik Institute, Harvard Medical School, Boston & Co-Director of the Paul F. Glenn Center for Biology of Aging Research, honorary Professor at the University of Sydney, and co-founder of the journal Aging.
The Sinclair lab works to understand the molecular underpinnings of aging and approaches to slow and reverse the process to improve human health
David A. Sinclair obtained a BS and a Ph.D. at UNSW, worked as a postdoctoral researcher at M.I.T., was hired at Harvard Medical School in 1999 as an Assistant Professor, and promoted to tenured Professor in 2008. His book Lifespan: Why We Age and Why We Don't Have To, a NYT bestseller, is published in more than 20 languages.
Dr. Sinclair is an inventor on more than 50 patents, 170 papers, an h-index of 103 & cited 73,000+ times. His more than 40 awards include an Excellence in Teaching Award, Harvard, AFAR Fellowship, the Ellison Medical Foundation Scholarships, Genzyme Outstanding Achievement Award, Telluride Technology Award, Innovator of the Year, MERIT Award, Nathan Shock Award, Denham Harman Award, ASMR Medal, Advance Global Australian, Pioneer Award, TIME100's most influential people, TIME magazine's Healthcare 50, Irving Wright Award, AFAR, and is an Officer of the Order of Australia (AO).
He cofounded Sirtris Pharma (Cambridge; NASDAQ:SIRT, bought by GSK), Genocea (Cambridge, MA; NASDAQ:GNCA); Ovascience (NASDAQ:OVAS), Cohbar (Menlo Park NASDAQ:CWBR)), MetroBiotech, ArcBio, Liberty Biosecurity, Galilei, Immetas, EdenRoc Sciences and affiliates, and Life Biosciences and affiliates.